The Breast
Volume 19, Issue 1 , Pages 65-66 , February 2010

Sentinel node biopsy in breast cancer: Time has come to systematically perform it before planned axillary clearance

Received 8 September 2009 ,Accepted 14 October 2009.

References 

  1. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–398
  2. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. National Surgical Adjuvant Breast and Bowel project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–888
  3. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;20(23):7703–7720
  4. Benson JR, della Rovere GQ. Axilla management consensus group. Management of the axilla in women with breast cancer. Lancet Oncol. 2007;8:331–348
  5. Sleth JC. Anaphylaxis due to patent blue. Time to change dye?. Ann Fr Anesth Reanim. 2008;276:515
  6. Lanitis S, Filippakis G, Sidhu V, Al Mufti R, Lee TH, Hadjiminas DJ. Atypical anaphylactic reaction to Patent Blue during sentinel lymph node biopsy for breast cancer. Ann R Coll Surg Engl. 2008;90:338–339
  7. O'Leary MR, Smith MS. Penicillin anaphylaxis. Am J Emerg Med. 1986;4:241–247
  8. East JM, Valentine CS, Kanchev E, Blake GO. Sentinel lymph node biopsy for breast cancer using methylene blue dye manifests a short learning curve among experienced surgeons: a prospective tabular cumulative sum (CUSUM) analysis. BMC Surg. 2009;27(9):2
  9. www.clinicaltrials.gov[accessed august 2009]
  10. Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–1151
  11. Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66
  12. de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;13(361):653–663
  13. Marrazzo A, Taormina P, Gebbiab V, David M, Riili I, Lo Gerfo D, et al Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?. Chir Ital. 2007;59:693–699
  14. Langer I, Guller U, Hsu-Schmitz SF, Ladewig A, Viehl CT, Moch H, et al. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. Eur J Surg Oncol. 2009;35:805–813

PII: S0960-9776(09)00135-0

doi: 10.1016/j.breast.2009.10.006

The Breast
Volume 19, Issue 1 , Pages 65-66 , February 2010

Article Tools